20.500.12556/RUL-136998 Synthesis of [$^2$H$_5$]baricitinib via [$^2$H$_5$]ethanesulfonyl chloride Baricitinib, typically applied as a treatment for rheumatoid arthritis, has recently attracted the attention of clinicians and researchers as a potential treatment for COVID-19. Naturally, there has been a need for the preparation of the isotope-labelled analogue of baricitinib to probe the pharmacokinetics of baricitinib in this new role. As such, we have developed a simple synthetic route to deuterated [$^2$H$_5$]baricitinib, facilitating its formation over four steps and in a 29% overall yield based on starting [$^2$H$_5$]ethanethiol (19% if we start with [$^2$H$_5$]bromoethane instead). A critical component of the overall process involves the synthesis of [$^2$H$_5$]ethanesulfonyl chloride, and we describe in detail the two routes that were explored to optimize this step. baricitinib COVID-19 deuteration deuterium-labelled SARS-CoV-2 isotopologue baricitinib COVID-19 devteracija označevanje z devterijem SARS-CoV-2 izotopolog true false true Angleški jezik Slovenski jezik Članek v reviji 2022-05-27 15:57:15 2022-05-27 15:57:16 2022-09-15 04:14:34 0000-00-00 00:00:00 2022 0 0 Str. 156-161 iss. 6 Vol. 65 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 547.1.057:615 1099-1344 10.1002/jlcr.3969 101564163 Labelled_Comp_Radiopharmac_-_2022_-_Jansen‐van_Vuuren_-_Synthesis_of__2H5_baricitinib_via__2H5_ethanesulfonyl_chloride.pdf Labelled_Comp_Radiopharmac_-_2022_-_Jansen‐van_Vuuren_-_Synthesis_of__2H5_baricitinib_via__2H5_ethanesulfonyl_chloride.pdf 1 50C3CE2B6201A9C425AA0E884EC2A949 c5b2c1718efef0b11794463b8312553e978ae824a4975bfc0e818bffc2b83d8c 11ed8d51-334e-11ed-92af-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=160928 https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jlcr.3969 1 c785e73f-ddc4-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=156841 Fakulteta za kemijo in kemijsko tehnologijo 0 0 0